Patents Assigned to FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
-
Patent number: 11565019Abstract: The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.Type: GrantFiled: April 8, 2019Date of Patent: January 31, 2023Assignees: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, SERVICIO ANDALUZ DE SALUDInventors: Rafael Campos Cuerva, Beatriz Fernandez Muñoz, Miguel Angel Gómez Bravo, Carmen Cepeda Franco, Jordi Muntane Relat
-
Patent number: 11213536Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.Type: GrantFiled: November 17, 2017Date of Patent: January 4, 2022Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUDInventors: Juan Carlos Morales Sánchez, Pablo Peñalver Puente, Francisco Javier Díaz Corrales, María Lourdes Valdés Sánchez, Ana Belén García Delgado, Adoración Montero Sánchez
-
Patent number: 10590434Abstract: The invention relates to expression systems useful for regulated expression of a gene of interest based on the constitutive expression of the original TetR repressor and the expression of the polynucleotide driven by a constitutive promoter operably linked to an operator sequence for a tetracycline operator sequence. The system can be provided as two different polynucleotides or as an all-in-one vector. The invention also relates to vectors, host cells and viral particles according to the invention as well as to the uses thereof for in vitro and in vivo production of products of interest or for therapy.Type: GrantFiled: October 16, 2017Date of Patent: March 17, 2020Assignees: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, INSTITUTO DE SALUD CARLOS IIIInventors: Francisco Martin Molina, Karim Benabdellah El Khlanji, Marien Cobo Pulido, Miguel Garcia Toscano, Pilar Munoz Fernandez
-
Patent number: 10053709Abstract: The present invention solves the problem of providing more efficient barrier insulators to avoid vector silencing and to increase expression in the setting of gene transfer vectors, more particularly in the setting of gene transfer retroviral vectors. In this sense, the authors of the present invention have developed an improved insulator element, namely element IS2, which comprises the following combination of nucleic acid molecules, namely nucleic acid molecule HS4-650 bp as shown in SEQ ID No 2 and a synthetic S/MAR nucleic acid molecule containing 5 M/SARs recognition signatures (MRS) as shown in SEQ ID no 1.Type: GrantFiled: March 13, 2014Date of Patent: August 21, 2018Assignees: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, INSTITUTO DE SALUD CARLOS IIIInventors: Francisco Martín Molina, Karim Benabdellah, Pilar Muñoz Fernández, Marién Cobo Pulido, Alejandra Gutierrez Guerrero
-
Patent number: 9822379Abstract: The invention relates to expression systems useful for regulated expression of a gene of interest based on the constitutive expression of the original TetR repressor and the expression of the polynucleotide driven by a constitutive promoter operably linked to an operator sequence for a tetracycline operator sequence. The system can be provided as two different polynucleotides or as an all-in-one vector. The invention also relates to vectors, host cells and viral particles according to the invention as well as to the uses thereof for in vitro and in vivo production of products of interest or for therapy.Type: GrantFiled: May 21, 2012Date of Patent: November 21, 2017Assignees: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, INSTITUTO DE SALUD CARLOS IIIInventors: Francisco Martin Molina, Karim Benabdellah El Khlanji, Marien Cobo Pulido, Miguel Garcia Toscano, Pilar Munoz Fernandez
-
Publication number: 20170211091Abstract: Provided herein are methods and compositions for inducing a somatic cell to acquire a less differentiated phenotype and for generating induced pluripotent stem cells (i PS cells) by inducing expression of ASF1A in the cell and/or by contacting the cell with GDF9. Also provided herein are compositions and methods for treating and/or diagnosing cancer and for identifying agents useful in the treatment and/or diagnosis of cancer.Type: ApplicationFiled: July 16, 2015Publication date: July 27, 2017Applicants: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, MICHIGAN STATE UNIVERSITY, INSTITUTO DE SALUD CARLOS IIIInventors: Jose B. Cibelli, María Elena Gonzalez-Muñoz
-
Publication number: 20160161504Abstract: The present invention refers to the use of tissue type plasminogen activator (tPA) and/or plasminogen activator inhibitor (PAI-1) for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from an inflammatory disease.Type: ApplicationFiled: August 1, 2014Publication date: June 9, 2016Applicants: Fundación Pública Andaluza Progreso y Salud, Instituto de Salud Carlos IIIInventors: Bernat Soria Escoms, Abdelkrim Hmadcha, Lourdes Acosta López, Natalia Escacena Acosta
-
Publication number: 20150218635Abstract: A method for obtaining useful data for the determination of an individual's risk of suffering from severe sensorineural hearing loss, preferably in Ménière's disease, primers useful in the determination and kit comprising same.Type: ApplicationFiled: December 14, 2012Publication date: August 6, 2015Applicants: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, SERVICIO ANDALUZ DE SALUD, AGENCIA PÚBLICA EMPRESARIAL SANITARIA HOSPITAL DE PONIENTE, SERVICIO GALEGO SAÚDE, FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FEInventors: Jose Antonio López Escamez, Miguel Ángel López Nevot, Irene Gazquez Pérez, Antonia María Moreno Casares, Alicia López Nevot, María Teresa Requena Navarro, Ismael Aran González, Andrés Soto Varela, Sofia Santos Pérez, Herminio Pérez Garrigues
-
Publication number: 20130210143Abstract: The present application relates to an LRH-1 agonist for use in the prevention of progressive loss of pancreatic ?-cells. It also relates to an LRH-1 agonist for use in the preservation or restoration of pancreatic ?-cells. Further, it relates to an LRH-1 agonist for use in the prevention or treatment of type I diabetes, the increment of survival of pancreatic ?-cells, the increment of the performance of pancreatic ?-cells, the increment of the survival of a ?-cell graft, the in vitro preservation of pancreatic ?-cells, maintaining insulin secretion and/or in a method of transplanting pancreatic islet cells.Type: ApplicationFiled: May 20, 2011Publication date: August 15, 2013Applicants: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUDInventors: Luc St-Onge, Benoit R. Gauthier, Mathurin Baquie, Claes B. Wollheim